# How Boehringer Ingelheim uses Owkin

As published on [owkin.com](https://www.owkin.com/newsfeed/owkin-to-license-k-pro-ai-scientist-and-multimodal-oncology-and-immunology-data-to-boehringer-ingelheim), September 2026. Captured by usedby on 2026-10-09.

- Company: [Boehringer Ingelheim](https://www.usedby.ai/companies/boehringer-ingelheim.md)
- Tool: [Owkin](https://www.usedby.ai/tools/owkin.md)
- Industry: [Biotech & Pharma](https://www.usedby.ai/companies/industry/biotech-pharma.md)

## What the story says

Boehringer Ingelheim licenses Owkin's K Pro AI Scientist along with multimodal oncology data, and new immunology data generated by Owkin, to speed up discovery across multiple indications. Its teams use K Pro as a single environment to query the data and run reproducible analyses for hypothesis generation, testing and prioritization.

Summary written by usedby from the source page, in English. The figures are those of Owkin and Boehringer Ingelheim, not ours.

> Boehringer Ingelheim’s teams will access and analyze this data through K Pro, which provides a single environment to interrogate data and run reproducible analyses. K Pro’s reasoning capabilities support human-led analysis and self-driven campaigns for hypothesis generation, testing and prioritization.

## What usedby checked

We compared the story with its live page on 2026-10-09.

- Checked: the passage quoted above is copied word for word from the page, near the name of Boehringer Ingelheim.
- Checked: the publication date is read from the page’s own metadata, never guessed.
- Checked: Boehringer Ingelheim uses Owkin. Confirmed line. Latest check across sources: 2026-10-09.
- Not checked: the result itself. We quote it; we did not measure it.

---
Source: https://www.usedby.ai/case-studies/boehringer-ingelheim-owkin · How we check: https://www.usedby.ai/methodology